.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Predict branded drug patent expiration
  • Set up watchlists for daily email updates

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Argus Health
Fuji
Daiichi Sankyo
Mallinckrodt
Johnson and Johnson
Cerilliant
Julphar
Merck
Accenture
Moodys

Generated: July 22, 2017

DrugPatentWatch Database Preview

Ambrisentan - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for ambrisentan and what is the scope of ambrisentan patent protection?

Ambrisentan
is the generic ingredient in one branded drug marketed by Gilead and is included in one NDA. There are five patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Ambrisentan has ninety-seven patent family members in thirty-three countries.

There are eight drug master file entries for ambrisentan. One supplier is listed for this compound.

Summary for Generic Name: ambrisentan

Tradenames:1
Patents:5
Applicants:1
NDAs:1
Drug Master File Entries: see list8
Suppliers / Packagers: see list1
Bulk Api Vendors: see list53
Clinical Trials: see list50
Patent Applications: see list1,390
Therapeutic Class:Respiratory Tract Agents
Formulation / Manufacturing:see details
Drug Prices:see low prices
DailyMed Link:ambrisentan at DailyMed

Pharmacology for Ingredient: ambrisentan

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Gilead
LETAIRIS
ambrisentan
TABLET;ORAL022081-002Jun 15, 2007RXYesYes9,549,926► Subscribe ► Subscribe
Gilead
LETAIRIS
ambrisentan
TABLET;ORAL022081-001Jun 15, 2007RXYesNo9,549,926► Subscribe ► Subscribe
Gilead
LETAIRIS
ambrisentan
TABLET;ORAL022081-001Jun 15, 2007RXYesNo9,474,752► Subscribe ► Subscribe
Gilead
LETAIRIS
ambrisentan
TABLET;ORAL022081-002Jun 15, 2007RXYesYes► Subscribe► Subscribe
Gilead
LETAIRIS
ambrisentan
TABLET;ORAL022081-001Jun 15, 2007RXYesNo8,377,933► Subscribe ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: ambrisentan

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Gilead
LETAIRIS
ambrisentan
TABLET;ORAL022081-002Jun 15, 20078,349,843► Subscribe
Gilead
LETAIRIS
ambrisentan
TABLET;ORAL022081-001Jun 15, 20077,601,730► Subscribe
Gilead
LETAIRIS
ambrisentan
TABLET;ORAL022081-001Jun 15, 20078,349,843► Subscribe
Gilead
LETAIRIS
ambrisentan
TABLET;ORAL022081-002Jun 15, 20077,601,730► Subscribe
Gilead
LETAIRIS
ambrisentan
TABLET;ORAL022081-001Jun 15, 20075,703,017► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: ambrisentan

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
RE42477Carboxylic acid derivatives, their preparation and use► Subscribe
6,600,043 Carboxylic acid derivatives, their preparation and use► Subscribe
7,109,205Carboxylic acid derivatives, their preparation and use► Subscribe
5,772,589 Measurement process for blood gas analysis sensors► Subscribe
7,119,097Carboxylic acid derivatives, their preparation and their use► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: ambrisentan

Country Document Number Estimated Expiration
HungaryT77443► Subscribe
Japan4512106► Subscribe
Eurasian Patent Organization201390428► Subscribe
Germany19512478► Subscribe
New Zealand707213► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: AMBRISENTAN

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0813Netherlands► SubscribePRODUCT NAME: AMBRISENTAN TOEGEPAST IN COMBINATIEBEHANDELING MET TADALAFIL; REGISTRATION NO/DATE: EU/1/08/451 (C(2008) 1637) 20151125
2016000039Germany► SubscribePRODUCT NAME: AMBRISENTAN IN VERWENDUNG IN DER KOMBINATIONSTHERAPIE MIT TADALAFIL; REGISTRATION NO/DATE: EU/1/08/451 20151120
0361Netherlands► Subscribe300361, 20151007, EXPIRES: 20201006
487Luxembourg► Subscribe91487, EXPIRES: 20201007
081Luxembourg► SubscribePRODUCT NAME: AMBRISENTAN UTILISE EN TRAITEMENT COMBINE AVEC TADALAFIL; FRIST REGISTRATION: 20151125
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Johnson and Johnson
US Department of Justice
Fuji
McKinsey
Dow
Cipla
Covington
US Army
AstraZeneca
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot